{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "conduct-of-studies", "type": "clause", "offset": [10, 28]}, {"key": "the-product", "type": "clause", "offset": [32, 43]}, {"key": "in-vitro", "type": "definition", "offset": [45, 53]}, {"key": "and-safety", "type": "clause", "offset": [100, 110]}], "size": 5, "samples": [{"hash": "j44PL5XGFzC", "uri": "/contracts/j44PL5XGFzC#preclinical-development", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 27.006844627, "published": true}, {"hash": "hlS0hCx7HWx", "uri": "/contracts/hlS0hCx7HWx#preclinical-development", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 26.749486653, "published": true}, {"hash": "lkKzWGggC3X", "uri": "/contracts/lkKzWGggC3X#preclinical-development", "label": "License, Development and Commercialization Agreement (Syndax Pharmaceuticals Inc)", "score": 25.3696098563, "published": true}], "snippet": "means the conduct of studies of the Product, in vitro or in animals, to assess the pharmacokinetics and safety (i.e., toxicology, carcinogenicity and mutagenicity) of the Product.", "hash": "f2f2a098934a13c6bfdda3e1de80374f", "id": 1}, {"snippet_links": [{"key": "relating-to", "type": "definition", "offset": [21, 32]}, {"key": "the-planning", "type": "clause", "offset": [33, 45]}, {"key": "in-vivo", "type": "definition", "offset": [103, 110]}, {"key": "animal-models", "type": "clause", "offset": [111, 124]}, {"key": "in-vitro", "type": "definition", "offset": [128, 136]}, {"key": "approval-of", "type": "definition", "offset": [174, 185]}, {"key": "regulatory-jurisdiction", "type": "definition", "offset": [204, 227]}, {"key": "in-the-territory", "type": "clause", "offset": [228, 244]}], "size": 5, "samples": [{"hash": "e9hT0DA33fj", "uri": "/contracts/e9hT0DA33fj#preclinical-development", "label": "License Agreement (Valentis Inc)", "score": 21.0, "published": true}], "snippet": "means all activities relating to the planning and execution of non-human studies conducted in relevant in vivo animal models or in vitro directed toward obtaining Regulatory Approval of a Product in each regulatory jurisdiction in the Territory.", "hash": "31c3dd8ed5878cc2637a7dae852b97ea", "id": 2}, {"snippet_links": [{"key": "clinical-development-activities", "type": "clause", "offset": [31, 62]}, {"key": "commencement-of-the", "type": "clause", "offset": [114, 133]}, {"key": "first-clinical-trial", "type": "definition", "offset": [134, 154]}, {"key": "clinical-studies", "type": "clause", "offset": [200, 216]}, {"key": "material-development", "type": "definition", "offset": [227, 247]}, {"key": "to-generate", "type": "definition", "offset": [276, 287]}], "size": 4, "samples": [{"hash": "Q2QFJpa3hi", "uri": "/contracts/Q2QFJpa3hi#preclinical-development", "label": "Collaboration and License Agreement (Homology Medicines, Inc.)", "score": 29.2217659138, "published": true}, {"hash": "kayjChU2uZp", "uri": "/contracts/kayjChU2uZp#preclinical-development", "label": "Collaboration and License Agreement (Homology Medicines, Inc.)", "score": 29.2108145106, "published": true}, {"hash": "6rYmvPxNCPe", "uri": "/contracts/6rYmvPxNCPe#preclinical-development", "label": "Collaboration and License Agreement (Homology Medicines, Inc.)", "score": 29.1642710472, "published": true}], "snippet": "means all pre-clinical and non-clinical Development activities for a Candidate or Product undertaken prior to the commencement of the first Clinical Trial for such Candidate or Product, including non-clinical studies and other material Development activities to be undertaken to generate data sufficient to enable the filing of an IND.", "hash": "39963d8ab136da88db3f3df62277cf5b", "id": 3}, {"snippet_links": [{"key": "commencement-of", "type": "clause", "offset": [10, 25]}, {"key": "animal-models", "type": "clause", "offset": [72, 85]}], "size": 4, "samples": [{"hash": "kdKejO5J5aV", "uri": "/contracts/kdKejO5J5aV#preclinical-development", "label": "Research and Development Agreement (Arqule Inc)", "score": 18.0, "published": true}, {"hash": "hy8dCGAAQ5y", "uri": "/contracts/hy8dCGAAQ5y#preclinical-development", "label": "Research and Development Agreement (Arqule Inc)", "score": 18.0, "published": true}], "snippet": "means the commencement of potency and efficacy testing of a compound in animal models.", "hash": "ace8ab76a56037982641541122bf279c", "id": 4}, {"snippet_links": [{"key": "preclinical-studies", "type": "definition", "offset": [12, 31]}, {"key": "with-respect-to", "type": "clause", "offset": [32, 47]}, {"key": "including-without-limitation", "type": "clause", "offset": [121, 149]}, {"key": "glp-toxicology-studies", "type": "definition", "offset": [159, 181]}, {"key": "cmc-section", "type": "definition", "offset": [211, 222]}, {"key": "development-of-a", "type": "clause", "offset": [356, 372]}, {"key": "other-non", "type": "clause", "offset": [442, 451]}, {"key": "clinical-testing", "type": "clause", "offset": [452, 468]}], "size": 4, "samples": [{"hash": "vEUVUaRLUM", "uri": "/contracts/vEUVUaRLUM#preclinical-development", "label": "Collaboration and License Agreement (Mirati Therapeutics, Inc.)", "score": 24.5181382615, "published": true}, {"hash": "8zjegJcO2km", "uri": "/contracts/8zjegJcO2km#preclinical-development", "label": "Collaboration and License Agreement (Mirati Therapeutics, Inc.)", "score": 24.3538672142, "published": true}], "snippet": "means those preclinical studies with respect to the Compounds and/or Products that are specifically required for an IND, including without limitation ADME and GLP toxicology studies, or studies required for the CMC section of an IND or an NDA. It is understood that \u201cpreclinical\u201d testing will continue after the filing of an IND in support of the clinical development of a Compound or Product, including ongoing toxicology, metabolic, PK and other non-clinical testing of such Compound or Product, and that \u201cPreclinical Development\u201d as used herein shall include such ongoing non-clinical testing.", "hash": "265c202b944f8054ad978552ece9d5d5", "id": 5}, {"snippet_links": [{"key": "clinical-development-activities", "type": "clause", "offset": [22, 53]}, {"key": "by-a-party", "type": "clause", "offset": [64, 74]}, {"key": "in-vivo", "type": "definition", "offset": [102, 109]}, {"key": "proof-of-concept-milestone", "type": "definition", "offset": [110, 136]}], "size": 3, "samples": [{"hash": "34NEGk2QIlT", "uri": "/contracts/34NEGk2QIlT#preclinical-development", "label": "License, Development and Commercialization Agreement (Cellectis S.A.)", "score": 30.311430527, "published": true}, {"hash": "f2UTxRR6kTr", "uri": "/contracts/f2UTxRR6kTr#preclinical-development", "label": "License, Development and Commercialization Agreement (Cellectis S.A.)", "score": 30.1909650924, "published": true}, {"hash": "4UEdRFs74FU", "uri": "/contracts/4UEdRFs74FU#preclinical-development", "label": "Product Development, Option, License and Commercialization Agreement (Cellectis S.A.)", "score": 26.1909650924, "published": true}], "snippet": "means any and all non-clinical Development activities performed by a Party until and including animal in vivo Proof of Concept Milestone.", "hash": "7dd6620b374edac7edae9051b332f1dd", "id": 6}, {"snippet_links": [{"key": "development-activities", "type": "definition", "offset": [12, 34]}], "size": 3, "samples": [{"hash": "dtDVJoBLRpL", "uri": "/contracts/dtDVJoBLRpL#preclinical-development", "label": "Collaboration Agreement (Nuvelo Inc)", "score": 21.0, "published": true}, {"hash": "dhQWaH9BWZw", "uri": "/contracts/dhQWaH9BWZw#preclinical-development", "label": "Collaboration Agreement (Nuvelo Inc)", "score": 21.0, "published": true}], "snippet": "means those Development activities performed before the filing of an IND.", "hash": "ae798ca8aae5156540cc76f271154fbe", "id": 7}, {"snippet_links": [{"key": "refer-to", "type": "definition", "offset": [6, 14]}, {"key": "relating-to", "type": "definition", "offset": [30, 41]}, {"key": "the-planning", "type": "clause", "offset": [42, 54]}, {"key": "in-vitro", "type": "definition", "offset": [103, 111]}, {"key": "in-vivo", "type": "definition", "offset": [127, 134]}, {"key": "animal-models", "type": "clause", "offset": [135, 148]}, {"key": "approval-of", "type": "definition", "offset": [186, 197]}, {"key": "regulatory-jurisdiction", "type": "definition", "offset": [216, 239]}, {"key": "in-the-territory", "type": "clause", "offset": [240, 256]}, {"key": "directly-related-to", "type": "definition", "offset": [355, 374]}, {"key": "development-activities", "type": "definition", "offset": [387, 409]}, {"key": "regulatory-affairs", "type": "clause", "offset": [423, 441]}, {"key": "outside-counsel", "type": "clause", "offset": [446, 461]}, {"key": "legal-services", "type": "definition", "offset": [473, 487]}], "size": 2, "samples": [{"hash": "joGALZP1c5V", "uri": "/contracts/joGALZP1c5V#preclinical-development", "label": "License Agreement (Techniclone Corp/De/)", "score": 18.0, "published": true}, {"hash": "eN7wqwQ2RGo", "uri": "/contracts/eN7wqwQ2RGo#preclinical-development", "label": "License Agreement (Techniclone Corp/De/)", "score": 18.0, "published": true}], "snippet": "shall refer to all activities relating to the planning and execution of non-human studies conducted in IN VITRO or in relevant IN VIVO animal models directed toward obtaining Regulatory Approval of a Product in each regulatory jurisdiction in the Territory. This includes preclinical testing, pharmacokinetics, toxicology, documentary and medical writing directly related to Preclinical Development activities, and related regulatory affairs and outside counsel regulatory legal services.", "hash": "4be391390d0d23d3e3bae4b63e46cd79", "id": 8}, {"snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "process-development-activities", "type": "clause", "offset": [75, 105]}, {"key": "relating-to", "type": "definition", "offset": [106, 117]}, {"key": "delivery-of-a", "type": "clause", "offset": [153, 166]}, {"key": "final-report", "type": "clause", "offset": [167, 179]}], "size": 2, "samples": [{"hash": "i9UmgP0NqYf", "uri": "/contracts/i9UmgP0NqYf#preclinical-development", "label": "Research Collaboration and License Agreement (Kite Pharma, Inc.)", "score": 27.6009582478, "published": true}, {"hash": "kh16RgRIgba", "uri": "/contracts/kh16RgRIgba#preclinical-development", "label": "Research Collaboration and License Agreement (Kite Pharma, Inc.)", "score": 26.2292950034, "published": true}], "snippet": "means, with respect to a particular Program, any research, preclinical and process development activities relating to such particular Program, up to the delivery of a Final Report.", "hash": "f3dfe424b4da08876a12cc7f7a3a459c", "id": 9}, {"snippet_links": [{"key": "development-of", "type": "clause", "offset": [104, 118]}, {"key": "other-compounds", "type": "definition", "offset": [119, 134]}, {"key": "other-products", "type": "clause", "offset": [150, 164]}, {"key": "in-vitro", "type": "definition", "offset": [215, 223]}, {"key": "in-vivo", "type": "definition", "offset": [227, 234]}, {"key": "similar-activities", "type": "clause", "offset": [440, 458]}, {"key": "with-respect-to-an", "type": "clause", "offset": [494, 512]}, {"key": "and-tools", "type": "clause", "offset": [604, 613]}, {"key": "software-and-databases", "type": "clause", "offset": [660, 682]}, {"key": "in-connection-with", "type": "clause", "offset": [716, 734]}, {"key": "the-activities", "type": "clause", "offset": [742, 756]}, {"key": "in-clauses", "type": "clause", "offset": [767, 777]}], "size": 2, "samples": [{"hash": "5AQa82CxtYo", "uri": "/contracts/5AQa82CxtYo#preclinical-development", "label": "Other Products Collaboration Agreement (Maxygen Inc)", "score": 21.0, "published": true}, {"hash": "4a4vmTqYVdH", "uri": "http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTI2NjZ8Q2hpbGRJRD0tMXxUeXBlPTM=&t=1", "label": "phx.corporate-ir.net", "score": 10.1704312115, "published": false}], "snippet": "means any and all processes and activities for the discovery and research of Other Protein Variants and development of Other Compounds and associated Other Products including those processes and activities, whether in vitro or in vivo conducted to: (i) discover, screen, optimize, clone, express, purify, formulate, characterize or enhance any Other Compound, including synthesis or Shuffling of any Other Compound, conjugation thereof, or similar activities; (ii) perform IND Enabling Studies with respect to an Other Compound and (iii) discover, develop, optimize, characterize or enhance technologies and tools including assays, screens, biological models, software and databases reasonably for the support of or in connection with any of the activities described in clauses (i) and (ii) above or development or manufacture.", "hash": "a6cdbf7588f3d45fd34a3c3e901ad68c", "id": 10}], "next_curs": "CmQSXmoVc35sYXdpbnNpZGVyY29udHJhY3RzckALEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIgcHJlY2xpbmljYWwtZGV2ZWxvcG1lbnQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 55, "title": "Preclinical Development", "snippet": "means the conduct of studies of the Product, in vitro or in animals, to assess the pharmacokinetics and safety (i.e., toxicology, carcinogenicity and mutagenicity) of the Product.", "id": "preclinical-development", "examples": ["The Preclinical Plan will include a description of the specific activities to be performed by CytomX in support of the <strong>Preclinical Development</strong> Program, the number of qualified CytomX FTEs to perform the activities in support of the <strong>Preclinical Development</strong> Program, projected timelines for completion of such activities and, as applicable, provisions for the supply of Compound by CytomX to BMS.", "If BMS has concerns regarding any specific scientist assigned to the <strong>Preclinical Development</strong> Program, such concerns shall be communicated to the JRC for its consideration.", "If CytomX develops any assays, that are not Tools, used in the <strong>Preclinical Development</strong> Program, upon request by BMS, CytomX shall transfer to BMS the CytomX Materials and Information to enable BMS to use such assays in support of BMS\u2019 research and development activities under this Agreement.", "The purpose of the Preclinical Plan is to detail the responsibilities and activities of CytomX and BMS with respect to carrying out the <strong>Preclinical Development</strong> Program.", "Each Party shall use good faith Diligent Efforts to perform the <strong>Preclinical Development</strong> Program, including its responsibilities under the Preclinical Plan.", "Upon reasonable request by BMS, for purposes of supporting the Development of a Product, CytomX shall provide BMS with additional data, results and other information with respect to the work performed by CytomX in the performance of the <strong>Preclinical Development</strong> Program.", "The <strong>Preclinical Development</strong> Program will be conducted by each Party in good scientific manner, and in compliance with all applicable good laboratory practices, and applicable legal requirements, to attempt to achieve efficiently and expeditiously the objectives of the <strong>Preclinical Development</strong> Program.", "As needed, the JRC shall establish subcommittees and working groups that will report to the JRC to further the objectives of the <strong>Preclinical Development</strong> Program.", "CytomX and BMS will provide reports and analyses at each JRC meeting, and more frequently upon reasonable request by the JRC, detailing the current status of the <strong>Preclinical Development</strong> Program, including the utilization of the CytomX FTE resources.", "Subject to the terms and conditions of this Agreement, BMS hereby grants back to CytomX a limited, non-exclusive, non-sublicensable, royalty-free license BMS intellectual property rights covering the BMS Information or Materials provided to CytomX and any Sole Inventions owned by BMS, solely to conduct the <strong>Preclinical Development</strong> Program, and not for any other purpose."], "related": [["clinical-development", "Clinical Development", "Clinical Development"], ["experimental-development", "experimental development", "experimental development"], ["commercial-development", "Commercial Development", "Commercial Development"], ["infill-development", "Infill development", "Infill development"], ["initial-development-plan", "Initial Development Plan", "Initial Development Plan"]], "related_snippets": [], "updated": "2025-07-06T21:58:36+00:00"}, "json": true, "cursor": ""}}